28-Year Survival following Several Metastasectomies, Going through 8th Line Systemic Therapy in a Case of mRCC
Metastatic renal cell carcinoma (mRCC) has been one of the most treatment-resistant cancers because of its unpredictable clinical course, resistance to chemo- and radiotherapy, and the limited response to immunotherapy and targeted agents. We present a case of long-term survival, that is, 28 years,...
Saved in:
| Main Authors: | A. Magdy, K. Bretterbauer, S. Hruby, T. Kunit, D. Colleselli, G. Janetschek, M. Mitterberger |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2015-01-01
|
| Series: | Case Reports in Urology |
| Online Access: | http://dx.doi.org/10.1155/2015/523258 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Laparoscopic Treatment of a Spontaneously Ruptured Kidney (Wunderlich Syndrome)
by: Katharina Maria Bretterbauer, et al.
Published: (2015-01-01) -
Expanding Treatment Options in mUC and mRCC
by: Richard Cathomas
Published: (2022-12-01) -
Eosinophils as a predictive marker of treatment-related adverse events in mRCC patients treated with first-line immune-checkpoint inhibitor combination therapy
by: Tatsushi Kawada, et al.
Published: (2025-07-01) -
Exceptional Response in a Patient with mRCC Through Precision-Guided Treatment Involving Immunotherapy Rechallenge with Temsirolimus and Bevacizumab
by: Ashkan Adibi, et al.
Published: (2025-05-01) -
Commentary: Sodium levels and immunotherapy efficacy in mRCC patients with bone metastases: sub analysis of Meet-Uro 15 study
by: Mehmet Fatih Ozbay
Published: (2024-11-01)